False Claims Act - G2 Intelligence

Whistleblowers: SCOTUS Gives DOJ Wider Authority to Dismiss Meritless Qui Tam Cases

Ruling could spell good news for labs and other healthcare providers targeted by whistleblowers in False Claims Act qui tam lawsuits.

Start a Free Trial for immediate access to this article

Already a member? Log in here

False billing of urine drug tests (UDTs) continues to be a focus for enforcement agencies in 2023, here’s how to avoid compliance issues.

Start a Free Trial for immediate access to this article

Already a member? Log in here

Recent cases involve COVID-19 fraud, UDTs, and the latest HIPAA Right of Access settlement.

Start a Free Trial for immediate access to this article

Already a member? Log in here

While the last few weeks haven’t seen many lab-related enforcement actions, several healthcare companies had to pay big.

In recent key cases, the national drug retailer must stand trial for failing to protect customers from faulty Theranos products.

Start a Free Trial for immediate access to this article

Already a member? Log in here